--- title: "Weekly Recap | Gilead Sciences +4.44%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/301467014.md" description: "Gilead Sciences (GILD) climbed 4.44% this week to close at $151.17, outperforming the S&P 500 by roughly 3.29 percentage points; the index rose 1.15% over the same period. The first half of the week was choppier: shares opened Monday at $143.21 and slipped to a weekly low of $142.598 on Tuesday. Sentiment recovered from midweek, with the stock back above $146 on Wednesday and a stronger Friday push to a weekly high of $151.44 before finishing near that level. The 6." datetime: "2026-10-10T06:37:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301467014.md) - [en](https://longbridge.com/en/news/301467014.md) - [zh-HK](https://longbridge.com/zh-HK/news/301467014.md) generator: "portal-rs" --- # Weekly Recap | Gilead Sciences +4.44%, most brokers rate it buy ## The Week Gilead Sciences (GILD) climbed 4.44% this week to close at $151.17, outperforming the S&P 500 by roughly 3.29 percentage points; the index rose 1.15% over the same period. The first half of the week was choppier: shares opened Monday at $143.21 and slipped to a weekly low of $142.598 on Tuesday. Sentiment recovered from midweek, with the stock back above $146 on Wednesday and a stronger Friday push to a weekly high of $151.44 before finishing near that level. The 6.17% weekly amplitude left the stock just under the 60-day range high of $154.2. ## Key Events The week brought several partnership and platform updates. On Monday, Nurix and Gilead extended the research term for an oncology programme by two years for a $10 million fee. On Tuesday, Gilead rolled out disease-specific wellness tools with the Calm app, and on Wednesday it signed a five-year DevOps agreement with Cognizant. Friday saw fresh attention on how Gilead’s earnings beat has changed its investment story, followed by UBS sticking to its buy rating in the evening, and weekend coverage noted the stock outperforming competitors on a strong trading day. These developments coincide with renewed biotech interest, though the link to the week’s price move is best read as coincident rather than causal. ## Analyst Ratings Across 28 firms covering the stock, 16 rate it buy, 6 rate it overweight, 5 hold, and 1 underweight, with no sell ratings or no-opinion calls; the consensus rating is buy. The consensus target price is $159.38, about 5.43% above the week’s close. Targets range from $126 to $180, placing the consensus towards the lower-middle part of that band without extreme dispersion. Within the biotechnology industry, Gilead ranks 8th out of 508 stocks. ## The Week Ahead The macro calendar is the main focus next week. Tuesday brings the NFIB small business optimism index and existing home sales figures, while Wednesday’s CPI and core CPI prints will be watched closely, with core CPI seen at 2.5% after a prior 2.4%. Those numbers could shape risk appetite and biotech fund flows, while Gilead closes the week near the top of its 60-day range, leaving the sustainability of this move tied to the market’s repricing of rates and growth. ## In Short This week’s tension sits between a constructive sell-side picture — consensus buy rating and a target above spot — and more mixed near-term flows. On the latest trading day, small and medium orders were net buyers while large orders were net sellers, leaving direction unresolved. Valuation shows a PB near 15.85x, with a negative TTM P/E. With the stock near the top of its 60-day range, next week’s CPI-driven macro updates may determine whether the recovery extends, and the key is whether volume and flow direction can confirm the move. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) ## Related News & Research - [BUZZ-Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead](https://longbridge.com/en/news/301846539.md) - [Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments](https://longbridge.com/en/news/301871452.md) - [Vir Biotechnology partners with Gilead to develop PRO-XTEN dual-masked T-cell engagers for solid tumors](https://longbridge.com/en/news/301842991.md) - [Sandisk Stock Is Falling Thursday: What's Going On?](https://longbridge.com/en/news/301982790.md) - [Peter Schiff Warns Trump’s ‘Booming’ Stock Market Boast Is a Mirage: 479 Stocks Hit 52-Week Lows on Wednesday, While Only 60 Set Highs](https://longbridge.com/en/news/301958076.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**